Highlights Selective degradation of pathogenic proteins is a promising strategy to drug 'undruggable' targets. Established degrader technologies such as PROTAC are extremely promising but still have limitations. The lysosome is a major degradation pathway utilized by cells to degrade extracellular and intracellular content. New technologies such as LYTAC, AUTAC, and ATTEC may have potential applications in several diseases by exploiting the lysosome for targeted degradation.
